Insights | Denuo

Denuo named Best Law Firm at 2026 Russia M&A Awards

Denuo has been named Best Law Firm at 2026 Russia M&A Awards.

One inspection – one fee? A new turn in customs disputes

In this legal update, we would like to draw your attention to a very important decision of the Arbitrazh Court of the Rostov Region dated 9 April 2026, in case No. A53-16734/25Decision of the Arbitrazh Court of the Rostov Region dated 9 April 2026 in case No. А53-16734/25, which could potentially change the current practice of calculating state duties when challenging decisions of customs authorities.

Gift of commercial immovable property between relatives who are entrepreneurs

In April 2026, the Supreme Court issued a decision in the case of IE Khabieva E.V., in which it clarified whether gifts of commercial real estate between close relatives who are individual entrepreneurs are subject to personal income tax.

21 / 04 / 2610:30 msk

Consequences of breaching a corporate agreement: theory, practice, recommendations

16 / 04 / 2611:00 msk

2026 foreign economic activities digest: news on legislation and cases, customs risks and solutions for business

Denuo tops 2025 Kommersant rating

Denuo received 24 firm ratings in the 2025 Legal Market Leaders guide. The ratings are based on multistage research by Kommersant, Russia’s leading publishing house.

01 / 04 / 2614:00 msk

M&A transactions in the new reality: current legal issues

31 / 03 / 2610:30 msk

Confirmation of resolutions adopted by a general meeting of participants (shareholders) and of the composition of participants (shareholders) present at their adoption

Denuo’s team leads Russia’s M&A for ninth consecutive year

For the ninth consecutive year, Denuo’s team has been recognised as the highest-ranked legal advisor in Russia for M&A deal count, according to Mergers.ru league tables.

Constitutional court ruling on compulsory licences

The Constitutional Court has regulated the application of the “compulsory licensing” mechanism to combat right holders maintaining “unreasonably high” prices for pharmaceuticals, with the caveat that this is a necessary measure to protect consumers from the abuse of intellectual property rights by bad faith persons.